GlassScriptPhysician profile
Jamal A Abukhaled
NPI 1518285451
$6,413.58
in general payments reported to CMS, 2019-2025
27 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,093 · 2020: $220 · 2021: $191 · 2022: $547 · 2023: $1,075 · 2024: $1,255 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,206 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,206.03 |
| Education | $156.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,886.23 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $503.16 | 2019-2025 | Farxiga |
| Alexion Pharmaceuticals, INC. | $495.06 | 2019-2025 | Ultomiris, Soliris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.45 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $376.34 | 2019-2025 | Jynarque |
| Amgen INC. | $359.58 | 2022-2025 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $358.83 | 2021-2024 | Lupkynis |
| Travere Therapeutics, INC. | $300.09 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.62 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $205.01 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $201.92 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $197.08 | 2022-2025 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $156.86 | 2020-2024 | Acthar |
| Vantive US Healthcare LLC | $117.02 | 2025 | Renal - Acute |
| Shield Therapeutics INC | $100.12 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ablative Solutions, INC. | $86.97 | 2020 | |
| Daiichi Sankyo INC. | $62.98 | 2022-2023 | Injectafer |
| Ardelyx, INC. | $55.21 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $53.91 | 2025 | |
| Opko Pharmaceuticals, LLC | $51.29 | 2022-2023 | Rayaldee |
| Scpharmaceuticals INC. | $43.40 | 2025 | |
| Apellis Pharmaceuticals, INC. | $31.47 | 2025 | Empaveli |
| Vifor Pharma, INC. | $30.10 | 2023 | Veltassa, Korsuva |
| Janssen Biotech, INC. | $26.13 | 2021 | |
| Chiesi USA, INC. | $25.48 | 2025 | Elfabrio |
| Horizon Therapeutics Plc | $23.02 | 2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $18.25 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Abukhaled listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.